Letter to the Editor
Sir: The recent Glaxo Wellcome-sponsored supplement to the Journal entitled "Beyond SSRIs" provides clinicians with useful information regarding the treatment of depression and discusses our bupropion product. I would like to provide clarification on some aspects of the supplement relating to bupropion.
From the Editors
Are you a healthcare provider?
Add your NPI to personalize your JCP experience.
This PDF is free for all visitors!